Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Novo and Lilly led the growth of the obesity drug market with the injectable GLP-1 medications Wegovy and Zepbound
Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells
For comparison, tirzepatide (Mounjaro, Zepbound) has a slightly lower constipation rate at 14-17% across doses, possibly because the GIP receptor component partially counteracts GLP-1's motility effects in some patients
This approachaddressing the whole person rather than just prescribing medicationreflects our commitment to functional medicine principles and optimized outcomes
US$ 29.03
US$ 21.31
US$ 27.32
US$ 23.51
